Company: SXTPW
Filing Date: 2025-07-07
Form Type: S-1
Source: 0001213900-25-061842
Chunk: 46

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-07-07
Form: S-1
Chunk 46
---
 as part of your investment decision to assess whether the net proceeds will
be used appropriately. Because of the number and variability of factors that will determine our use of the net proceeds from this offering,
their ultimate use may vary substantially from their currently intended use. Our management might not apply our net proceeds in ways that
ultimately increase the value of your investment. We currently intend to use the net proceeds to us from this offering for working
capital and general corporate purposes.

Our expected use of net proceeds from this offering
represents our current intentions based upon our present plans and business condition. As of the date of this prospectus, we cannot predict
with certainty all of the particular uses for the net proceeds to be received upon the completion of this offering, or the amounts that
we will actually spend on the uses set forth above. The amounts and timing of our actual use of the net proceeds will vary depending on
numerous factors. As a result, our management will have broad discretion in the application of the net proceeds, and investors will be
relying on our judgment regarding the application of the net proceeds of this offering.

The failure by our management to apply these funds
effectively could harm our business. Pending their use, we may invest the net proceeds from this offering in short-term, investment-grade,
interest-bearing securities. These investments may not yield a favorable return to our stockholders. If we do not invest or apply the
net proceeds from this offering in ways that enhance stockholder value, we may fail to achieve expected financial results, which could
cause our stock price to decline.

Investors in this offering may experience future dilution as a result of this and future equity offerings.

In order to raise additional capital, we may in
the future offer additional shares of our common stock or other securities convertible into or exchangeable for our common stock. Investors
purchasing our shares or other securities in the future could have rights superior to existing common stockholders, and the price per
share at which we sell additional shares of our common stock or other securities convertible into or exchangeable for our common stock
in future transactions may be higher or lower than the price per share in this offering.

<div align='center'>21</div>

The issuance of shares upon exercise of derivative securities may cause immediate and substantial dilution to our existing stockholders.

The issuance of shares upon exercise of options
or warrants and settlement of any outstanding restricted stock units may result in substantial dilution to the interests of other stockholders
since these selling